CDSCO Flags Paracetamol, Pan D, And 51 Other Drugs As ‘Not of Standard Quality’ In Latest Report
CDSCO Flags Paracetamol, Pan D, And 51 Other Drugs As ‘Not of Standard Quality’ In Latest Report ( Representational Image )
The Central Drugs Standards Control Organisation (CDSCO) has identified over 50 drugs, including widely used medications such as Paracetamol, Pan D, and calcium supplements, as “not of standard quality” in its August 2024 quality check report. This announcement has raised concerns over the safety and effectiveness of these commonly prescribed drugs.
Among the flagged medications are paracetamol, vitamin D and calcium supplements, high blood pressure drugs, and anti-diabetic pills. These were listed under the “Not of Standard Quality (NSQ)” category based on random sampling conducted by state drug officers as part of the regulator’s monthly inspection.
Some of the drugs that failed the quality tests include vitamin C and D3 tablets, Shelcal, vitamin B complex, anti-acid medication Pan-D, 500 mg paracetamol tablets, anti-diabetic drug Glimepiride, and high blood pressure medication Telmisartan. These products were manufactured by companies such as Hetero Drugs, Alkem Laboratories, Hindustan Antibiotics Limited (HAL), and others.
Additionally, metronidazole, a common drug for treating stomach infections, and Shelcal, a well-known calcium and vitamin D3 supplement, were also flagged. The CDSCO’s report included two lists: one with 48 failed drugs and another featuring 5 spurious drugs, along with responses from their manufacturers.
Earlier in August, the CDSCO banned over 156 fixed-dose drug combinations nationwide due to potential risks to human health.
